MedImmune, Inc. broke ground on the expansion of the biologics manufacturing facility at its existing site in Frederick, MD. Synagis, a monoclonal antibody approved by the FDA to help prevent infectious disease, is currently produced at the site. The $250-million expansion is the first phase of a multi-phase construction project. “This groundbreaking highlights MedImmune’s leadership in the state’s biotechnology industry, and its expertise in cell culture-based manufact...